Regulation of Insulin Sensitivity by the Ubiquitin Ligase Siah2

泛素连接酶 Siah2 对胰岛素敏感性的调节

• 批准号: 8829242
• 负责人: ZELPHA ELIZABETH FLOYD
• 金额: $ 29.6万
• 依托单位: LSU PENNINGTON BIOMEDICAL RESEARCH CTR
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-01 至 2018-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8829242
• 关键词: Adipocytes; Adipose tissue; Agreement; Animal Model; Antidiabetic Drugs; Chronic; Chronic Disease; Data; Development; Dietary Fats; Disease; Drosophila genus; Enzymes; Gene Expression; Goals; Health; Homologous Gene; Human; Hypertrophy; In Vitro; Inflammation; Inflammatory; Insulin; Insulin Resistance; Intake; Learning; Ligands; Link; Lipids; Mediating; Metabolic syndrome; Modification; Molecular; Mus; Non-Insulin-Dependent Diabetes Mellitus; Nonesterified Fatty Acids; Nuclear Hormone Receptors; Obesity; PPAR gamma; Pathway interactions; Peroxisome Proliferation; Pharmaceutical Preparations; Play; Post-Translational Protein Processing; Production; Proteins; Public Health; Regulation; Regulatory T-Lymphocyte; Research; Resistance; Role; Signal Pathway; Signal Transduction; Small Interfering RNA; System; Testing; Thiazolidinediones; Tissues; Triglycerides; Ubiquitin; adipocyte biology; base; blood glucose regulation; carbohydrate metabolism; cytokine; glucose metabolism; insight; insulin sensitivity; interest; lipid metabolism; macrophage; mouse model; multicatalytic endopeptidase complex; new therapeutic target; novel; novel therapeutics; obesity treatment; polypeptide; prevent; receptor; response; screening; ubiquitin ligase

DESCRIPTION (provided by applicant): Obesity is a major public health problem due to the increase in obesity-related chronic diseases such as type 2 diabetes. The development of obesity-related insulin resistance and type 2 diabetes can be linked to dysregulation of the ability of adipose tissue to adequately store energy in the form of triglycerides, leading to ectopc lipid accumulation in non-adipose tissues. The nuclear hormone receptor peroxisome proliferation-activated receptor gamma (PPARγ) in adipocytes is a key factor in integrating lipid metabolism with glucose homeostasis and insulin sensitivity. Activation of PPARγ by the thiazolidinedione (TZD) class of anti-diabetic drugs is associated with expansion of the adipose tissue and enhanced ability of the adipose tissue to store dietary lipids. These drugs alter PPARγ activity and PPARγ protein levels, an indication that understanding the link between PPARγ activity and PPARγ protein stability may offer new insights into how obesity contributes to NIDDM. PPARγ stability in adipocytes is regulated by enzymes of the ubiquitin proteasome pathway, a highly selective signaling pathway that targets proteins to the proteasome by tagging the protein with multiple ubiquitin polypeptides. Using siRNA-based screening, we identified a ubiquitin ligase, Siah2 that regulates PPARγ protein levels and PPARγ activity in adipocytes. Our preliminary studies using a Siah2KO mouse model show Siah2 regulates PPARγ protein levels and inflammation in adipose tissue and that eliminating Siah2 prevents obesity-related insulin resistance. We hypothesize that Siah2-dependent regulation of PPARγ activity links obesity with adipose tissue inflammation and insulin resistance. Our goal is to provide mechanistic insight into the role of Siah2 in controlling the relationship between PPARγ protein levels, insulin sensitivity and inflammation in adipose tissue. In Specific Aim 1, we will test the hypothesis that Siah2-dependent modification of PPARγ limits PPARγ activity by increasing ligand-dependent proteasomal degradation of PPARγ. Specific aim 2 will assess the effect of Siah2 on adipose tissue inflammation. In specific aim 3, we will test the hypothesis that Siah2 in adipocytes regulates systemic insulin sensitivity via regulation of PPARγ activity and lipid partitioning between adipose and non-adipose tissue. Together, these studies will provide new insight into the relationship between PPARγ activity and the role of adipose tissue in regulating insulin sensitivity and will advance our goal of determining if the ubiquitin-proteasome system represents a novel therapeutic target in the treatment of obesity-related insulin resistance and type 2 diabetes.

描述（由申请人提供）：由于肥胖相关慢性疾病（如2型糖尿病）的增加，肥胖是一个主要的公共卫生问题。肥胖相关的胰岛素抵抗和2型糖尿病的发展可能与脂肪组织以甘油三酯形式充分储存能量的能力失调有关，导致非脂肪组织中的异位脂质积累。脂肪细胞核激素受体过氧化物酶体增殖激活受体γ（过氧化物酶体增殖激活受体γ，过氧化物酶体增殖激活受体γ）是整合脂代谢、葡萄糖稳态和胰岛素敏感性的关键因子。噻唑烷二酮（TZD）类抗糖尿病药物激活PPARγ与脂肪组织扩张和脂肪组织储存膳食脂质的能力增强相关。这些药物改变了PPARγ活性和PPARγ蛋白水平，这表明了解PPARγ活性和PPARγ蛋白稳定性之间的联系可能会为肥胖如何导致NIDDM提供新的见解。脂肪细胞中的PPARγ稳定性受泛素蛋白酶体途径的酶调节，泛素蛋白酶体途径是一种高度选择性的信号传导途径，通过用多种泛素多肽标记蛋白质将蛋白质靶向蛋白酶体。使用基于siRNA的筛选，我们鉴定了一种泛素连接酶Siah 2，其调节脂肪细胞中的PPARγ蛋白水平和PPARγ活性。我们使用Siah 2KO小鼠模型的初步研究表明，Siah 2调节脂肪组织中的PPARγ蛋白水平和炎症，消除Siah 2可以预防肥胖相关的胰岛素抵抗。我们推测，Siah 2依赖性调节的过氧化物酶体增殖物激活受体γ活性与肥胖、脂肪组织炎症和胰岛素抵抗有关。我们的目标是提供Siah 2在控制脂肪组织中的PPARγ蛋白水平、胰岛素敏感性和炎症之间的关系中的作用的机制性见解。在具体目标1中，我们将测试 假设Siah 2依赖性修饰的PPARγ通过增加配体依赖性蛋白酶体降解的PPARγ限制了PPARγ活性。具体目标2将评估Siah 2对脂肪组织炎症的影响。在具体目标3中，我们将检验脂肪细胞中的Siah 2通过调节PPARγ活性和脂肪与非脂肪组织之间的脂质分配来调节全身胰岛素敏感性的假设。总之，这些研究将为PPARγ活性与脂肪组织在调节胰岛素敏感性中的作用之间的关系提供新的见解，并将推进我们的目标，即确定泛素-蛋白酶体系统是否代表肥胖相关胰岛素抵抗和2型糖尿病治疗的新治疗靶点。